You are using an outdated browser. Please upgrade your browser to improve your experience.


Ligand Summary
has antiangiogenic activity; consists of the second and third Ig domains of VEGFR1 and VEGFR2, respectively, fusion to the Fc region of IgG1; putative antineoplastic agent that binds all VEGF-A isoforms; possible medicine for eye disorders
Synonyms & Links
DrugCentral: 4916
LyCHI:  aflibercept

Target Activities